(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
3 days till quarter result
(tns 2024-05-07)
Expected move: +/- 22.49%
-2.56% $ 22.47
Live Chart Being Loaded With Signals
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A...
Stats | |
---|---|
Dzisiejszy wolumen | 81 878.00 |
Średni wolumen | 120 683 |
Kapitalizacja rynkowa | 56.22M |
EPS | $0 ( 2024-03-12 ) |
Następna data zysków | ( $0 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.515 |
ATR14 | $1.161 (5.17%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-08-11 | Flagship Ventures Fund V General Partner Llc | Sell | 113 960 | Common Stock |
2023-08-11 | Eli Lilly & Co | Buy | 1 718 493 | Common Stock |
2023-08-11 | Cole Douglas G. | Sell | 683 | Stock Option (Right to Buy) |
2023-08-11 | Cole Douglas G. | Sell | 683 | Stock Option (Right to Buy) |
2023-08-11 | Oesterle Stephen N. | Sell | 683 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
68.78 |
Last 96 transactions |
Buy: 15 034 169 | Sell: 5 311 777 |
Wolumen Korelacja
Sigilon Therapeutics, Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
PATI | 0.984 |
ADMS | 0.969 |
RESN | 0.964 |
CNCE | 0.931 |
MIRO | 0.919 |
RXDX | 0.913 |
APM | 0.911 |
EPZM | 0.908 |
OCUL | 0.908 |
ZGNX | 0.906 |
10 Najbardziej negatywne korelacje | |
---|---|
TTCF | -0.938 |
CPSH | -0.925 |
DMRC | -0.918 |
CDAK | -0.912 |
AZYO | -0.911 |
CCOI | -0.907 |
OFS | -0.901 |
DTEA | -0.897 |
GSMG | -0.889 |
LUNA | -0.889 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Sigilon Therapeutics, Korelacja - Waluta/Towar
Sigilon Therapeutics, Finanse
Annual | 2022 |
Przychody: | $12.94M |
Zysk brutto: | $12.94M (100.00 %) |
EPS: | $-1.340 |
FY | 2022 |
Przychody: | $12.94M |
Zysk brutto: | $12.94M (100.00 %) |
EPS: | $-1.340 |
FY | 2021 |
Przychody: | $9.60M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-2.43 |
FY | 2020 |
Przychody: | $13.37M |
Zysk brutto: | $13 374.00 (0.10 %) |
EPS: | $-7.55 |
Financial Reports:
No articles found.
Sigilon Therapeutics,
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej